Infection News Feeds
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT-006 FLU-IVIG)
Canvassing your interest in participating in the Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT-006 FLU-IVIG)
As you are all aware, influenza is responsible for thousands of hospitalizations and deaths each year worldwide and newer treatments are urgently needed. One possible new treatment approach involves passive immunotherapy with hyperimmune IV immunoglobulin (IVIG). The FLU-IVIG study is exploring whether giving a single infusion of this IVIG as an adjunct to standard-of-care therapies (antivirals etc) can improve clinical outcomes for adults hospitalised with moderate to severe influenza. The study is funded by the NIH, conducted by the INSIGHT network and coordinated in the UK by the MRC Clinical trial Unit at UCL.
More detailed information about the study funding, inclusion/exclusion criteria, key study requirements, and opportunities for investigators to publish within the network are included in the summary attached.
To express interest in becoming a FLU-IVIG site, please contact the FLU study team based at the MRC CTU on email@example.com.